CROI 2022: Telomere shortening associated with TAF but not TDF in CHARTER study

Back to the "HIV and Co-Infections News" list
A poster just presented at CROI 2022 from the CHARTER study reported that TAF was associated with telomere shortening, but not tenofovir disoproxil. [1]This was in 121 HIV positive people initialling assessed from 2003–7 and again a median of 12 years later, but this had the significant limitation that baseline samples were not available on TAF because it was not yet available.Last month a prospective 17-year study from the Swiss HIV Cohort reported that untreated HIV was associated with significant reductions in telomere length (TL) but that effective ART stopped further damage. This study did not find any association with individual HIV drugs. [2, 3]By Simon Collins, HIV i-Base

References

  1. Upal R et al. Tenofovir alafenamide is associated with shorter telomere length in people with HIV. CROI 2022. Poster abstract 625.
    https://ww2.aievolution.com/cro2201/index.cfm?do=abs.viewAbs&abs=2431
  2. HIV-associated reductions in telomere length are stopped by effective ART. HTB February 2022.
    https://i-base.info/htb/42052
  3. Schoepf IC et al for the Swiss HIV Cohort Study. Telomere length declines in persons living with HIV before antiretroviral therapy start but not after viral suppression: a longitudinal study over >17 years. J Infect Dis. 2021 Dec 15:jiab603. doi: 10.1093/infdis/jiab603. (21 December 2021).
    https://pubmed.ncbi.nlm.nih.gov/34910812

 

All HIV i-Base reports from CROI 2022.

 

Source : HIV i-Base

Get involved

Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?

Subscribe

Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.